Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Influence of publication of US and European prostate cancer screening trials on PSA testing practices.

Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW.

J Natl Cancer Inst. 2011 Mar 16;103(6):520-3. doi: 10.1093/jnci/djr007. Epub 2011 Feb 28.

PMID:
21357307
2.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force..

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
3.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
4.

[Advancements in PSA-based screening for prostate cancer].

Ito K.

Rinsho Byori. 2004 Jul;52(7):611-7. Review. Japanese.

PMID:
15344561
5.

Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts.

Rove KO, Crawford ED.

World J Urol. 2012 Apr;30(2):137-42. doi: 10.1007/s00345-011-0799-4. Epub 2011 Nov 25. Review.

PMID:
22116599
6.
7.
8.

Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.

Lim LS, Sherin K; ACPM Prevention Practice Committee..

Am J Prev Med. 2008 Feb;34(2):164-70. doi: 10.1016/j.amepre.2007.10.003. Review. Erratum in: Am J Prev Med. 2008 May;34(5):454.

PMID:
18201648
10.

[Screening for prostate cancer--what does the evidence show?].

Borre M, Iversen P.

Ugeskr Laeger. 2007 May 14;169(20):1887-8. Review. Danish.

PMID:
17553362
11.

[Descriptive epidemiology of prostate cancer in Japan and Western countries].

Wakai K.

Nihon Rinsho. 2005 Feb;63(2):207-12. Review. Japanese.

PMID:
15714967
12.

Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.

Pron G.

Ont Health Technol Assess Ser. 2015 May 1;15(10):1-64. eCollection 2015. Review.

13.

A literature review of cost-effectiveness analyses of prostate-specific antigen test in prostate cancer screening.

Garg V, Gu NY, Borrego ME, Raisch DW.

Expert Rev Pharmacoecon Outcomes Res. 2013 Jun;13(3):327-42. doi: 10.1586/erp.13.26. Review.

PMID:
23763530
14.

Screening for prostate cancer: have we resolved the controversy?

Zhu X, Roobol MJ, Schröder FH.

Curr Opin Support Palliat Care. 2010 Sep;4(3):121-6. doi: 10.1097/SPC.0b013e32833abc21. Review.

PMID:
20489646
15.

Prostate-specific antigen and prostate cancer mortality: a systematic review.

Wallner LP, Jacobsen SJ.

Am J Prev Med. 2013 Sep;45(3):318-26. doi: 10.1016/j.amepre.2013.04.015. Review.

PMID:
23953359
16.

The Melbourne Consensus Statement on the early detection of prostate cancer.

Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ.

BJU Int. 2014 Feb;113(2):186-8. doi: 10.1111/bju.12556. Review.

17.

Risk stratification in prostate cancer screening.

Roobol MJ, Carlsson SV.

Nat Rev Urol. 2013 Jan;10(1):38-48. doi: 10.1038/nrurol.2012.225. Epub 2012 Dec 18. Review. Erratum in: Nat Rev Urol. 2013 May;10(5):248.

PMID:
23247693
18.

The prostate-specific antigen screening conundrum: examining the evidence.

O'Rourke ME.

Semin Oncol Nurs. 2011 Nov;27(4):251-9. doi: 10.1016/j.soncn.2011.07.003. Review.

PMID:
22018404
19.

PSA screening: a public health dilemma.

Mandelson MT, Wagner EH, Thompson RS.

Annu Rev Public Health. 1995;16:283-306. Review.

PMID:
7543756
20.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context.

Berg CD.

Acta Oncol. 2011 Jun;50 Suppl 1:12-7. doi: 10.3109/0284186X.2010.531283. Review.

PMID:
21604935

Supplemental Content

Support Center